Abnormal Platelet Aggregation Studies
Acquired causes of platelet dysfunction:
Ingestion of aspirin or aspirin-like compounds or NSAIDs
Impaired renal function
Exposure to cardiopulmonary bypass
Presence of a paraprotein
Congenital causes of platelet dysfunction:
Storage pool disease
Disorders of thromboxane production or action
Suggested Additional Lab Testing
Platelet aggregation studies with characteristic response patterns for the different agonists help identify Glanzmann thrombasthenia, Bernard-Soulier disease, aspirin ingestion, and defects in thromboxane production or action.
Plasma or serum BUN and creatinine and urinalysis to assess renal function should be ordered.
If aspirin ingestion is suspected but denied by patient, measurement of salicylates (metabolites of aspirin) may prove useful.
Bone marrow biopsy may be useful if myeloproliferative disease is suspected.
Serum protein electrophoresis can reveal a paraprotein. To identify platelet granule storage pool disease, assays for the granular contents of platelets can be performed, but these are complex, costly, and rarely performed.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Moving Targets: Off-Label Prescribing of Targeted Therapies
- New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma
- 2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
- Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer
- Immunotherapy Combo in Head and Neck Cancer Shows Activity in Phase 2 Trial
- Nutraceuticals/Supplements and Cancer Prevention: All Hype?
- Plastics and Cancer
- Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited
- POT1 Revealed as a Sarcoma Predisposition Gene
- IMRT Linked to Fewer Instances of Local Recurrence in Sarcoma: A Long-Term Follow-Up
- Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid Tumors
- Palliative Care and Survivorship